Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


HBM portfolio company Newron Pharmaceuticals goes public:
Invested capital almost doubled


Baar, 8 December 2006 -- The IPO price for shares in the Italian biotechnology company Newron Pharmaceuticals was set yesterday. The IPO price of CHF 55.00 per share is 78% higher than the CHF 30.94 purchase price paid by HBM BioVentures. The Newron Pharmaceuticals IPO alone thus increases HBM BioVentures' net asset value by CHF 12.8 million, or CHF 1.14 per share. The first trading day for Newron Pharmaceuticals on the SWX Swiss Exchange (ticker: NWRN) is set to be 12 December 2006.

Newron Pharmaceuticals develops drugs to treat disorders of the central nervous system, especially Parkinson's disease, epilepsy and pain. The compounds are currently undergoing phase II and III clinical trials. In October 2006, Newron announced a major licensing deal with Swiss biotechnology company Serono in the field of Parkinson's disease.

In February and December 2005, HBM BioVentures invested a total of CHF 16.5 million in Newron Pharmaceuticals as lead investor.

Additional details can be found on the Newron Pharmaceuticals website at www.newron.com.

Further information can also be obtained from Dr. Andreas Wicki, CEO of HBM BioVentures Ltd, on: +41 41 768 11 08, andreas.wicki@hbmbioventures.com.

Profile
HBM BioVentures invests in the human medicine, biotechnology and medical technology sectors. As a holding company it manages a mature, widely diversified portfolio of private and small-cap public companies. Investors appreciate HBM BioVentures as an integral part of their healthcare portfolio which gives them access to this newly created investment segment with its high value creation potential. HBM BioVentures is an active investor which finances, accompanies and supports portfolio companies as a key partner. With net assets of over CHF 1 billion, HBM BioVentures is one of the most liquid investments in this sector. Lean structures ensure a competitive cost structure, while wide-ranging expertise, operating industrial experience, highest professional standards and transparency distinguish the company. HBM BioVentures Ltd has a broad shareholder base.
xx


Publisher Contact Information:

HBM Partners AG
+41 41 768 11 08
andreas.wicki@hbmbioventures.com

Company profile of HBM Partners AG
Past press releases of HBM Partners AG.

Data


26,609
Tech investments
From our Online Data Service
17,183
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 25€24.0MInternet commerce
Jan 24€11.0MBiopharmaceuticals
Jan 24N/ABiotechnology
Jan 24€104.0MBusiness applications
Jan 24€15.0MBiopharmaceuticals
Jan 24€1.5MInternet services
Jan 23€3.2MBusiness applications

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises 1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.